Mitoxantrone. A review of its pharmacological properties and use in acute nonlymphoblastic leukaemia

Drugs and Aging

Volumn 9, Issue 2, 1996, Pages 122-147

  Dunn, Christopher J ^a   Goa, Karen L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTARABINE; DAUNORUBICIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MITOXANTRONE;

ABDOMINAL PAIN; ACUTE NONLYMPHOCYTIC LEUKEMIA; AGED; ALOPECIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BLEEDING; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; DIARRHEA; DRUG DISTRIBUTION; DRUG DNA INTERACTION; DRUG EFFICACY; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; FEVER; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA REMISSION; LEUKOPENIA; LIVER TOXICITY; NAUSEA; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; SEPSIS; STOMATITIS; VOMITING;

EID: 0029767924     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199609020-00007     Document Type: Review

References (132)

1. Faulds D, Balfour JA, Chrisp P, et al. Mitoxantrone: a review of ils pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. Drugs 1991 Mar; 41: 400-49
2. Johnson PRE, Hunt LP, Yin JA. Prognostic factors in elderly patients with acute myeloid leukaemia: development of a model to predict survival. Br J Haematol 1993 Oct; 85: 300-6
3. Murdock KC, Child RG, Fabio PF, et al. Antitumor agents. 1. 1,4-Bis[(aminoalkyl)amino]-9,10-anthracenediones. J Med Chem 1979; 22(9): 1024-30
4. Capranico G, Zunino F. DNA topoisomerase-trapping antitumour drugs. Eur J Cancer 1992; 28A (12): 2055-60
5. Liu LF. DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 1989; 58: 351-75
6. Wang JC. DNA topoisomerases: why so many? J Biol Chem 1991 Apr 15; 266 (11): 6659-62
7. Wang JC. DNA topoisomerases. Annu Rev Biochem 1985; 54: 665-97
8. Fox ME, Smith PJ. Long-term inhibition of DNA synthesis and the persistence of trapped topoisomerase II complexes in determining the toxicity of the DNA intercalators mAMSA and mitoxantrone. Cancer Res 1990 Sep 15; 50: 5813-8
9. Capranico G, De Isabella P, Tinelli S, et al. Similar sequence specificity of mitoxantrone and VM-26 stimulation of in vitro DNA cleavage by mammalian DNA topoisomerase II. Biochemistry 1993 Mar 30; 32: 3038-46
10. Kolodziejczyk P, Reszka K, Lown JW. Enzymatic oxidation activation and transformation of the antitumor agent mitoxantrone. Free Radic Biol Med 1988; 5: 13-25
11. Fisher GR, Patterson LH. DNA strand breakage by peroxidase-activated mitoxantrone. J Pharm Pharmacol 1991; 43: 65-8
12. Bowden GT, Roberts R, Alberts DS, et al. Comparative molecular pharmacology in leukemic L1210 cells of the anthracene anticancer drugs mitoxantrone and bisantrene. Cancer Res 1985 Oct; 45: 4915-20
13. Gorczyca W, Bigman K, Mittelman A, et al. Induction of DNA strand breaks associated with apoptosis during treatment of leukemias. Leukemia 1993 May; 7: 659-70
14. Ray S, Ponnathpur V, Huang Y, et al. 1-β-D-arabinofuranosylcytosine-, mitoxantrone-, and paclitaxel-induced apoptosis in HL-60 cells: improved method for detection of internucleosomal DNA fragmentation. Cancer Chemother Pharmacol 1994 Aug; 34: 365-71
15. Takeuchi N, Nakamura T, Takeuchi F, et al. Inhibitory effect of mitoxantrone on activity of protein kinase C and growth of HL60 cells. J Biochem Tokyo 1992 Dec; 112: 762-7
16. Bhalla K, Ibrado AM, Tourkina E, et al. High-dose mitoxantrone induces programmed cell death or apoptosis in human myeloid leukemia cells. Blood 1993 Nov 15; 82: 3133-40
17. Chandrasekaran B, Dimling J, Capizzi RL. Cross-resistance of menogaril and mitoxantrone in a subline of P388 leukemia resistant to doxorubicin. Cancer Treat Rep 1987 Feb; 71: 195-6
18. Schabel Jr FM, Corbett TH, Griswold Jr DP, et al. Therapeutic activity of mitoxantrone and ametantrone against murine tumors. Cancer Treat Rev 1983; 10 Suppl. B: 13-21
19. Grant S, Arlin Z, Gewirtz D, et al. Effect of pharmacologically relevant concentrations of mitoxantrone on the in vitro growth of leukemic blast progenitors. Leukemia 1991 Apr; 5: 336-9
20. Satyamoorthy K, Chitnis MP, Pradhan SG, et al. Modulation of mitoxantrone cytotoxicity by verapamil in human chronic myeloid leukemia cells. Oncology 1989; 46: 128-31
21. Chitnis MP, Satyamoorthy K, Pradhan SG, et al. Modulation of sensitivity to mitoxantrone in human chronic myeloid leukemia cells by the antidepressant sintamil. Oncology 1988; 45: 292-6
22. Juvekur AS, Chitnis MP, Advani SH. In vitro modulation of adriamycin and mitoxantrone cytotoxicity by hyperthermia and diazepam, in human chronic myeloid leukemia cells. Neoplasm 1987; 34: 199-204
23. Juvekar AS, Chitnis MP, Adwankar MK, et al. Effect of mitoxantrone on human chronic myeloid leukemia cells in vitro, combined with hyperthermia. Neoplasma 1986; 33: 477-82
24. Kano Y, Suzuki K, Akutsu M, et al. Effects of mitoxantrone in combination with other anticancer agents on a human leukemia cell line. Leukemia 1992 May; 6: 440-5
25. Vogel CL. Combination chemotherapy with vinorelbine (Navelbine) and mitoxantrone for metastatic breast cancer: a review. Semin Oncol 1995 Apr; 22 Suppl. 5: 61-5
26. Rosenthal CJ, Ibrahim A, Rambhia H, et al. Paclitaxel (Taxol)-mitoxantrone salvage therapy in metastatic carcinoma of the breast - phase I/II study [abstract no. 172]. In: Perry MC, editor. Proceedings of the Thirtieth Annual Meeting of the American Society of Clinical Oncology; 1994 May 14-17; Dallas.
27. Krehmeier C, Zühlsdorf M, Büchner T, et al. Synergistic cytotoxicity of cytosine arabinoside and mitoxantrone for K562 and CFU-GM. Hamatol Bluttransfus 1990; 33: 129-32
28. Fountzilas G, Inoue S, Ohnuma T. Schedule-dependent interaction of cytarabine plus doxorubicin or cytarabine plus mitoxantrone in acute myelocytic leukemia cells in culture. Leukemia 1990 May; 4: 321-4
29. Heinemann V, Murray D, Walters R, et al. Mitoxantrone-induced DNA damage in leukemia cells is enhanced by treatment with high-dose arabinosylcytosine. Cancer Chemother Pharmacol 1988; 22: 205-10
30. Gerlach JH, Kartner N, Bell DR, et al. Multidrug resistance. Cancer Surv 1986; 5 (1): 25-46
31. Multidrug resistance in cancer [edilorial]. Lancet 1989 Nov 4; 2: 1075-6
32. Kamath N, Grabowski D, Ford J, et al. Overexpression of P-glycoprotein and alterations in topoisomerase-II in P388 mouse leukemia cells selected in vivo for resistance to mitoxantrone. Biochem Pharmacol 1992 Sep 1; 44: 937-45
33. Michieli M, Damiani D, Geromin A, et al. Overexpression of multidrug resistance-associated p170-glycoprotein in acute non-lymphocytic leukemia. Eur J Haematol 1992 Feb; 48: 87-92
34. Ludescher C, Eisterer W, Hilbe W, et al. Low frequency of activity of P-glycoprotein (P-170) in acute lymphoblastic leukemia compared to acute myeloid leukemia. Leukemia 1995 Feb; 9: 350-6
35. Schuurhuis GJ, Broxterman HJ, Ossenkoppele GJ, et al. Functional multidrug resistance phenotype associated with combined Overexpression of Pgp/MDR1 and MRP together with 1-β-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeolid leukemia. Clin Cancer Res 1995 Jan; 1: 81-93
36. Marie JP, Helou C, Thevenin D, et al. In vitro effect of P-glycoprotein (P-gp) modulators on drug sensitivity of leukemic progenitors (CFU-L) in acute myelogenous leukemia (AML). Exp Hematol 1992 Jun; 20: 565-8
37. Pincus R, Goldman ID. Evidence for impaired mitoxantrone and vinblastine binding in P388 murine leukemia cells with multidrug resistance. Biochem Pharmacol 1990 Dec 15; 40: 2625-35
38. Laurent G, Bailly JD, Skladanowski A, et al. Natural resistance of acute myeloid leukemia to mitoxantrone: role of drug transport, topoisomerase II activity, and cell death pathway [abstract no. 2067]. Blood 1995 Nov 15; 86 (10) Suppl. 1: 520a
39. Juvekar AS, Chitnis MP. Circumvention of drug resistance of P388/R cells by the combination of adriamycin and mitoxantrone with hyperthermia (42°C). Neoplasma 1991; 38: 207-11
40. Sargent J, Elgie A, Alton P, et al. In vitro modification of resistance to MDR-related drugs in acute myeloid leukaemia (AML) [abstract]. Br J Cancer 1994 Jun; 69: 1192-3
41. Parekh H, Chitnis M. Differential alteration of cellular lipids in drug sensitive and resistant P388 leukemia cells by clofibrate: effects on mitoxantrone cytotoxicity. Tumori 1991 Apr; 77: 105-11
42. Kornblau SM, Andreeff F, Koller C, et al. Double anthracycline (mitoxantrone + idarubicin) therapy with cyclosporin A (CSA) to block multidrug resistance (MDR) as salvage therapy for relapsed or refractory acute myelogenous leukemia (R-AML) [abstract no. 2043]. Blood 1995 Nov 15; 86 (10) Suppl. 1: 514a
43. Kornblau SM, Estey E, Consoli U, et al. A phase I study of mitoxantrone + VP-16 with multidrug (MDR) blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia (R-AML) [abstract no. 2044]. Blood 1995 Nov 15; 86 (10) Suppl. 1: 514a
44. Ehninger G, Schuler U, Proksch B, et al. Pharmacokinetics and metabolism of mitoxantrone. A review. Clin Pharmacokinet 1990 May; 18: 365-80
45. Hulhoven R, Dumont E, Harvengt C. Plasma kinetics of mitoxantrone in leukemic patients. Med Oncol Tumor Pharmacother 1984; 1 (3): 201-4
46. Gruber A, Liliemark J, Tidefelt U, et al. Pharmacokinetics of mitoxantrone in plasma and leukemic cells during treatment of patients with acute non-lymphocytic leukemia. Leuk Lymphoma 1992 Apr; 6: 493-6
47. Schleyer E, Kamischke A, Kaufmann CC, et al. New aspects on the pharmacokinetics of mitoxantrone and ils two major metabolites. Leukemia 1994 Mar; 8: 435-40
48. Alberts DS, Peng YM, Bowden GT, et al. Mechanism of action and pharmacokinetics of Novantrone® in intravenous and intraperitoneal therapy. In: Coltman Jr CA, editor. The current status of Novantrone®: Proceedings of a Symposium held March 21-24, 1985, at Scottsdale, Arizona. New York: Park Row Publishers, 1985: 15-21
49. Alberts DS, Peng Y-M, Leigh S, et al. Disposition of mitoxantrone in cancer patients. Cancer Res 1985; 45: 1879-84
50. Ehninger G, Proksch B, Heinzel G, et al. Clinical pharmacology of mitoxantrone. Cancer Treat Rep 1986; 70: 1373-8
51. Smyth JF, Macpherson JS, Warrington PS, et al. The clinical pharmacology of mitozantrone. Cancer Chemother Pharmacol 1986; 17: 149-52
52. Van Belle SJP, de Planque MM, Smith IE, et al. Pharmacokinetics of mitoxantrone in humans following single-agent infusion or intra-arterial injection therapy or combined-agent infusion therapy. Cancer Chemother Pharmacol 1986; 18: 27-32
53. Stewart DJ, Green RM, Mikhael NZ, et al. Human autopsy tissue concentrations of mitoxantrone. Cancer Treat Rep 1986; 70: 1255-61
54. Burns CP, Haugstad BN, North JA. Membrane transport of mitoxantrone by L1210 leukemia cells. Biochem Pharmacol 1987 Mar 15; 36: 857-60
55. Greidanus J, de Vries EGE, Mulder NH, et al. A phase 1 pharmacokinetic study of 21-day continuous infusion mitoxantrone. J Clin Oncol 1989; 7: 790-7
56. Ehninger G, Proksch B, Heinzel G, et al. The pharmacokinetics and metabolism of mitoxantrone in man. Invest New Drugs 1985; 3 (2): 109-16
57. Azuno Y, Kaku K, Fujita N, et al. Mitoxantrone and etoposide in breast milk [letter]. Am J Hematol 1995 Feb; 48: 131-2
58. Chiccarelli FS, Morrison JA, Cosulich DB, et al. Identification of human urinary mitoxantrone metabolites. Cancer Res 1986; 46: 4858-61
59. Miser JS, Malspeis L, Staubus AE, et al. Plasma pharmacokinetics of mitoxantrone in pediatric patients. Proc Am Assoc Cancer Res 1983; 24: 132
60. McCauley DL. Treatment of adult acute leukemia. Clin Pharm 1992 Sep; 11: 767-96
61. Devine SM, Larson RA. Acute leukemia in adults: recent developments in diagnosis and treatment. CA Cancer J CHn 1994; 44: 11-2
62. Mastrianni DM, Tung NM, Tenen DG. Acute myelogenous leukemia: current treatment and future directions. Am J Med 1992; 92: 286-95
63. Liu Yin JA. Acute myeloid leukaemia in the elderly: biology and treatment. Br J Haematol 1993; 83: 1-6
64. Champlin RE, Gajewski JL, Golde DW. Treatment of acute myelogenous leukemia in the elderly. Semin Oncol 1989 Feb; 16 (1): 51-6
65. Rees JKH, Gray RG, Swirsky D, et al. Principal results of the Medical Research Council's 8th Acute Myeloid Leukaemia trial. Lancet 1986 Nov 29; 2: 1236-41
66. Feldman EJ. Acute myelogenous leukemia in the older patient. Semin Oncol 1995 Feb; 22 Suppl. 1: 21-4
67. Phillips GL, Reece DE, Shepherd JD, et al. High-dose cytarabine and daunorubicin induction and postremission chemotherapy for the treatment of acute myelogenous leukemia in adults. Blood 1991 Apr 1; 77 (7): 1429-35
68. Bishop JF, Lowenthal RM, Joshua D, et al. Etoposide in acute nonlymphocytic leukemia. Blood 1990 Jan 1; 75 (1): 27-32
69. Liu-Yin JA, Johnson PR, Davies JM, et al. Mitozantrone and cytosine arabinoside as first-line therapy in elderly patients with acute myeloid leukaemia. Br J Haematol 1991 Nov; 79: 415-20
70. MacCallum PK, Rohatiner AZS, Davis CL, et al. Mitoxantrone and cytosine arabinoside as treatment for acute myeloblastic leukemia in older patients. Ann Hematol 1995 Jul; 71: 35-9
71. Rodríguez-Morales A, López JL, Sánchez P, et al. Mitoxantrone (MTZ) and ARA-C: high remission rale as first line therapy for acute myeloid leukemia (AML) [abstract no. 499]. 5th International Symposium on Therapy of Acute Leukemias: 1991; Rome, Italy.
72. Samir Motawy M, Salfiti R, Khalifa F, et al. Experience with combinations containing mitoxantrone in the treatment of adult acute leukemias. J Chemother 1989 Apr; 1: 123-7
73. Arlin Z, Case Jr DC, Moore J, et al. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Leukemia 1990 Mar; 4: 177-83
74. Bueno J, Herrero E, López A, et al. Treatment of acute myeloid leukemia (AML) in old patients [abstract no. 516]. 5th International Symposium on Therapy of Acute Leukemias; 1991: Rome, Italy.
75. Pavlovsky S, Gonzalez Llaven J, Garcia Martinez MA, et al. A randomized study of mitoxantrone plus cytarabine versus daunomycin plus cytarabine in the treatment of previously untreated adult patients with acute nonlymphocytic leukemia. Ann Hematol 1994; 69: 11-5
76. Wahlin A, Hörnsten P, Hedenus M, et al. Mitoxantrone and cytarabine versus daunorubicin and cytarabine in previously untreated patients with acute myeloid leukemia. Cancer Chemother Pharmacol 1991 Oct; 28: 480-3
77. Bow EJ, Sutherland JA, Kilpatrick MG, et al. Therapy of untreated acute myeloid leukemia in the elderly: remission-induction using a non-cytarabine-containing regimen of mitoxantrone plus etoposide. J Clin Oncol 1996 Apr; 14 (4): 1345-52
78. Ehninger G, Fackler-Schwalbe E, Freund M, et al. Combination of mitoxantrone and etoposide in patients aged over 60 years with untreated acute myelogenous leukemia. Hamatol Bluttransfus 1990; 33: 316-7
79. Knauf WU, Berdel WE, Ho AD, et al. Combination of mitoxantrone and etoposide in the treatment of myelodysplastic syndromes transformed into acute myeloid leukemia. Leuk Lymphoma 1994 Feb; 12: 421-5
80. Seiter K, Feldman E, Beer M, et al. Phase II study of high dose mitoxantrone-based induction therapy in patients with acute myeloid leukemia [abstract]. Blood 1995 Nov 15; 86 (10) Suppl. 1: 780a
81. Shepherd JD, Barnett MJ, Brockington DA, et al. Induction and consolidation therapy with intermediate-dose cytarabine, mitoxantrone and etoposide in patients ≥ 60 years with acute myeloid leukemia (AML) [abstract]. Blood 1995 Nov 15; 86 (10) Suppl. 1: 522a
82. Visani G, Petti MC, Cenacchi A, et al. MEC (mitoxantrone, etoposide and intermediate dose cytarabine): and effective induction regimen for previously untreated acute non-lymphocytic leukemia. Leuk Lymphoma 1995 Nov; 19: 447-51
83. Björkholm M, Liliemark J, Gahrton G, et al. Mitoxantrone, etoposide and ara-C vs doxorubicin-DNA, ara-C, thioguanine, vincristine and prednisolone in the treatment of patients with acute myelocytic leukaemia. A randomized comparison. Eur J Haematol 1995 Jul; 55: 19-23
84. Wheatley K. Meta-analysis of randomized trials of idarubicin (IDAR) or mitoxantrone (MITO) versus daunorubicin (DNR) as induction therapy for acute myeloid leukaemia (AML) [abstract no. 1724]. Blood 1995 Nov 15; 86 (10) Suppl. 1
85. Feldman EJ, Alberts DS, Arlin Z, et al. Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia. J Clin Oncol 1993 Oct; 11: 2002-9
86. Feldman E, Seiter K, Linker C, et al. Intensive induction without consolidation in elderly patients with newly diagnosed acute myeloid leukemia (AML) [abstract no. 1004]. In: Perry MC, editor. Proceedings of the Thirty-First Annual Meeting of the American Society of Clinical Oncology; 1995 May 20-23; Los Angeles.
87. Paciucci PA, Davis RB, Holland JF, et al. Mitoxantrone and constant infusion etoposide for relapsed and refractory acute myelocytic leukemia. Am J Clin Oncol Cancer Clin Trials 1990 Dec; 13: 516-9
88. Archimbaud E, Leblond V, Michallet M, et al. Intensive sequential chemotherapy with mitoxantrone and continuous infusion etoposide and cytarabine for previously treated acute myelogenous leukemia. Blood 1991 May 1; 77: 1894-900
89. Walters RS, Kantarjian HM, Keating MJ, et al. Mitoxantrone and high-dose cytosine arabinoside in refractory acute myelogenous leukemia. Cancer 1988 Aug 15; 62: 677-82
90. Bezwoda WR, Bernasconi C, Hutchinson RM, et al. Mitoxantrone for refractory and relapsed acute leukaemia. Cancer 1990 Aug 1; 66: 418-22
91. Coccia-Portugal MA, Falkson G, Uys A. Mitoxantrone in the treatment of acute leukemia. Hamatol Bluttransfus 1990; 33: 318-21
92. Larson RA, Daly KM, Choi KE, et al. A clinical and pharmacokinetic study of mitoxantrone in acute nonlymphocytic leukemia. J Clin Oncol 1987 Mar; 5: 391-7
93. Vredenburgh JJ, McIntyre OR, Cornwell III GG, et al. Mitoxantrone in relapsed or refractory acute nonlymphocytic leukemia. Med Pediatr Oncol 1988; 16: 187-9
94. Brito-Babapulle F, Catovsky D, Newland AC, et al. Treatment of acute myeloid leukemia with intermediate-dose cytosine arabinoside and mitoxantrone. Semin Oncol 1987 Jun; 14 (2 Suppl. 1): 51-2
95. Harousseau JL, Milpied N, Briere J, et al. Mitoxantrone and intermediate-dose cytarabine in relapsed or refractory acute myeloblastic leukemia. Nouv Rev Fr Hematol 1990; 32 (4): 227-30
96. Hiddemann W, Aul C, Maschmeyer G, et al. High-dose versus intermediate dose cytosine arabinoside combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: results of an age adjusted randomized comparison. Leuk Lymphoma 1993; 10 Suppl.: 133-7
97. Hiddemann W, Kreutzmann H, Straif K, et al. Phase I/II trial of high-dose cytosine arabinoside and mitoxantrone in adult refractory acute myeloid leukemia. Hamatol Bluttransfus 1987; 30: 336-8
98. Keskin A, Tombuloglu M, Atamer MA, et al. Mitoxantrone and standard dose cytosine arabinoside therapy in refractory or relapsed acute leukemia. Acta Haematol 1994; 92 (1): 14-7
99. Liang R, Chiu E, Chan TK, et al. Salvage chemotherapy containing moderate-dose cytosine arabinoside and mitoxantrone for relapsed and resistant acute myeloid leukaemia. Cancer Chemother Pharmacol 1991 Apr; 28: 74-6
100. MacCallum PK, Davis CL, Rohatiner AZS, et al. Mitoxantrone and cytosine arabinoside as treatment for acute myelogenous leukemia (AML) at first recurrence. Leukemia 1993 Oct; 7: 1496-9
101. Paciucci PA, Cuttner J, Holland JF. Sequential intermediate-dose cytosine arabinoside and mitoxantrone for patients with relapsed and refractory acute myelocytic leukemia. Am J Hematol 1990 Sep; 35: 22-5
102. Paciucci PA, Dutcher JP, Cuttner J, et al. Mitoxantrone and ara-C in previously treated patients with acute myelogenous leukemia. Leukemia 1987 Jul; 1: 565-7
103. Martiat P, Ghilain JM, Ferrant A, et al. High-dose cytosine arabinoside and amsacrine or mitoxantrone in relapsed and refractory acute myeloid leukaemia: a prospective randomized study. Eur J Haematol 1990 Sep; 45: 164-7
104. O'Brien S, Kantarjian H, Estey E, et al. Mitoxantrone and high-dose etoposide for patients with relapsed or refractory acute leukemia. Cancer 1991 Aug 15; 68: 691-4
105. Daenen S, Löwenberg B, Sonneveld P, et al. Efficacy of etoposide and mitoxantrone in patients with acute myelogenous leukemia refractory to standard injection therapy and intermediate-dose cytarabine with amsidine. Leukemia 1994 Jan; 8: 6-10
106. Ho AD, Lipp T, Ehninger G, et al. Combination of mitoxantrone and etoposide in refractory acute myelogenous leukernia - an active and well-tolerated regimen. J Clin Oncol 1988 Feb; 6: 213-7
107. Lazzarino M, Morra E, Alessandrino EP, et al. Mitoxantrone and etoposide - an effective regimen for refractory or relapsed acute myelogenous leukemia. Eur J Haematol 1989 Nov; 43: 411-6
108. Rowe JM, Mazza JJ, Hines JD, et al. Mitoxantrone and etoposide in patients with relapsed and refractory acute non-lymphocytic leukemia. Hamatol Bluttransfus 1990; 33: 326-9
109. Amadori S, Arcese W, Isacchi G, et al. Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia. J Clin Oncol 1991 Jul; 9: 1210-4
110. Archimbaud E, Thomas X, Leblond V, et al. Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial. J Clin Oncol 1995 Jan; 13: 11-8
111. Björkholm M, Björnsdottir J, Stenke L, et al. Mitoxantrone, etoposide and cytarabine in the treatment of acute non-lymphocytic leukemia. Oncology 1990; 47: 112-4
112. Björkholm M. Mitoxantrone, etoposide and cytarabine in the treatment of acute myelocytic leukemia (AML). Haematol Bluttransfus 1994; 36: 216-20
113. Link H, Freund M, Diedrich H, et al. Mitoxantrone, cytosine arabinoside, and VP-16 in 36 patients with relapsed and refractory acute myeloid leukemia. Haematol Bluttransfus 1990; 33: 322-5
114. Spadea A, Petti MC, Fazi P, et al. Mitoxantrone, etoposide and intermediate-dose Ara-C (MEC): an effective regimen for poor risk acute myeloid leukemia. Leukemia 1993 Apr; 7: 549-52
115. Amrein PC, Davis RB, Mayer RJ, et al. Treatment of relapsed and refractory acute myeloid leukemia with diaziquone and mitoxantrone: a CALGB phase-I study. Am J Hematol 1990 Oct; 35: 80-3
116. Ohno R, Tomonaga M, Kobayashi T, et al. Effect of granulocyte-colony stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. N Engl J Med 1990; 323 (13): 871-7
117. Archimbaud E, Fenaux P, Reiffers J, et al. Granulocyte-macrophage colony-stimulating factor in association to timed-sequential chemotherapy with mitoxantrone, etoposide, and cytarabine for refractory acute myelogenous leukemia. Leukemia 1993 Mar; 7: 372-7
118. Mantovani L, Kämpfe D, Lehmann P, et al. Treatment of poorprognosis AML with rhGM-CSF and rhG-CSF for priming, followed by cytarabine plus mitoxantrone induction therapy: a phase I/II study [abstract no. 3062]. Blood 1995 Nov 15; 86 (10) Suppl. 1
119. Benjamin RS. Rationale for the use of mitoxantrone in the older patient: cardiac toxicity. Semin Oncol 1995 Feb; 22 (1 Suppl. 1): 11-3
120. Crossley RJ. Clinical safety and tolerance of mitoxantrone. Semin Oncol 1984 Sep; 11 (3) Suppl. 1: 54-8
121. Mather FJ, Simon RM, Clark GM, et al. Cardiotoxicity in patients treated with mitoxantrone: Southwest Oncology Group phase II studies. Cancer Treat Rep 1987 Jun; 71 (6): 609-13
122. Posner LE, Dukart G, Goldberg J, et al. Mitoxantrone: an overview of safety and toxicity. Invest New Drugs 1985; 3: 123-32
123. Immunex Corporation. Mitoxantrone for injection concentrate. Prescribing information. Seattle, Washington, USA, 1994.
124. Paxton A. Comment: mitoxantrone [letter]. Drug Intell Clin Pharm 1986 Jun; 20: 507-8
125. Leyden MJ, Sullivan JR, Cheng ZM, et al. Unusual side effect of mitoxantrone [letter]. Med J Aust 1983 Nov 12; 2: 514
126. Immunex Corporation. Mitoxantrone for injection concentrate. Technical monograph. Seattle, Washington, USA, 1994.
127. Dorr RT, Alberts DS, Soble M. Lack of experimental vesicant activity for the anticancer agents cisplatin, melphalan, and mitoxantrone. Cancer Chemother Pharmacol 1986; 16: 91-4
128. Peters FTM, Beijnen JH, ten Bokkel Huinink WW. Mitoxantrone extravasation injury [letter]. Cancer Treat Rep 1987; 71 (10): 992-3
129. Ketelby JW. Cytotoxic-drug extravasation [letter]. Med J Aust 1989 Jan 2; 150 (1): 52
130. Man A. Local tissue damage as a result of extravasation of mitozantrone [letter]. BMJ 1986 Jul 12; 293: 140
131. Spataro V, Cometta A, Glauser MP, et al. Should elderly patients with acute myeloid leukemia be treated by myelosuppressive chemotherapy? [in German]. Schweiz Med Wochenschr 1995 Mar 4; 125: 429-32
132. Buechner T, Hiddemann W. Treatment strategies in acute myeloid leukemia (AML). Blut 1990; 60: 61-7